Straits Times Index
3,379.12 +15.44 (+0.46%) Nikkei
27,509.46 +107.41 (+0.39%) Hang Seng
21,677.26 -281.10 (-1.28%) FTSE 100
7,820.16 +59.05 (+0.76%) BTC-USD
23,532.69 -290.07 (-1.22%) CMC Crypto 200
536.73 -8.59 (-1.57%)
Baxter International Inc. (BAX)
After hours:
| Previous close | 46.28 |
| Open | 46.42 |
| Bid | 0.00 x 1100 |
| Ask | 0.00 x 1400 |
| Day's range | 46.00 - 47.23 |
| 52-week range | 43.25 - 89.70 |
| Volume | |
| Avg. volume | 5,403,780 |
| Market cap | 23.699B |
| Beta (5Y monthly) | 0.59 |
| PE ratio (TTM) | 23.50 |
| EPS (TTM) | 2.00 |
| Earnings date | 09 Feb 2023 |
| Forward dividend & yield | 1.16 (2.54%) |
| Ex-dividend date | 01 Dec 2022 |
| 1y target est | 58.94 |
- Zacks
Earnings Preview: Baxter International (BAX) Q4 Earnings Expected to Decline
Baxter (BAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Business Wire
Miromatrix and Baxter Announce Collaborative Research Agreement Aiming to Advance Care for Patients with Acute Liver Failure
EDEN PRAIRIE, Minn. & DEERFIELD, Ill., February 01, 2023--Miromatrix Medical Inc. (NASDAQ: MIRO) and Baxter International Inc. (NYSE:BAX) today announced a collaborative research agreement to help support additional treatment options for patients with acute liver failure (ALF) in need of organ support therapies. As part of the collaboration, Miromatrix has created a new liver therapy called miroliverELAP that combines a Miromatrix single-use bioengineered liver with Baxter’s PrisMax system. Miro
- Zacks
Baxter (BAX) to Report Q4 Earnings: What's in the Cards?
Baxter's (BAX) fourth-quarter results are likely to reflect growth in elective surgical procedures, offset by currency and supply challenges. Hillrom's products are likely to have boosted sales.
